Radioimmunoassay for Determination of Serum Macrophage Migration Inhibitory Factor.
- Author:
Tae Sup LEE
1
;
Seok Hwan SHIN
;
Jee In SONG
;
Kwang Sun WOO
;
Wee Sup CHUNG
;
Chang Woon CHOI
;
Sang Moo LIM
Author Information
1. Laboratory of Cyclotron Application, Korea Institute of Radiological and Medical Science (KIRAMS), Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Macrophage migration inhibitory factor (MIF);
Radioimmunoassay;
Streptavidin;
Iodine-125;
Inflammatory diseases
- MeSH:
Communicable Diseases;
Humans;
Immunoradiometric Assay;
Macrophages*;
Radioactivity;
Radioimmunoassay*;
Sepsis;
Streptavidin;
Ultracentrifugation
- From:Korean Journal of Nuclear Medicine
2004;38(6):532-539
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: There has been a renewal of interest in Macrophage migration inhibitory factor (MIF), especially correlation in pathogenesis of sepsis by many infectious diseases and in regulation of host inflammatory and immune response. We developed immunoradiometric assay (IRMA) to determine serum human MIF concentration. MATERIALS AND METHODS: The IRMA system utilizes solid phase bound monoclonal anti-recombinant human MIF (rhMIF) antibody as a capture antibody, biotinylated polyclonal anti-rhMIF antibody as a detector antibody. We applied with rhMIF that concentration of standard solutions increased from 0 ng/ml to 100 ng/ml. We used 125I-streptavidin (SA) as radiotracer to determination of rhMIF concentration. Streptavidin was labeled with 125I by Chloramine-T method and 125I-SA was purified by ultracentrifugation. 125I-SA stability was evaluated by ITLC analysis at 4 degrees C and room temperatures until 60days. To validate IRMA system for MIF, we experimented intra-assay and inter-assay coefficients of variation, recovery test and dilution test. RESULTS: Radiolabeling yield of 125I-SA was 87% and purified 125I-SA retained above 99% radiochemical purity. 125I-SA showed above 93% stability in 4 degrees C until 60days that it is good for immunoradiometric assay as radiotracer. Plotted standard dose response curve showed that increased concentration of rhMIF linearly correlated (R2=0.99) with bound radioactivity of 125I-SA. The highest intra- and inter-assay coefficients of variation were 5.5% and 7.6%, respectively. The average of recovery of MIF in samples was 102%. In dilution test, linear response curves were obtained (R2=0.97). CONCLUSION: Radioimmunoassay using 125I-SA as radiotracer thought to be useful for the determination of serum MIF concentration, and further, its data will be used to evaluate the correlation between clinical significance and serum MIF concentration in patients with various inflammatory diseases.
